Prelude Therapeutics Incorporated
PRLD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $7,000 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $7,000 | $0 | $0 | $0 |
| % Margin | 100% | – | – | – |
| R&D Expenses | $117,995 | $103,393 | $92,889 | $86,778 |
| G&A Expenses | $28,719 | $28,884 | $30,651 | $26,957 |
| SG&A Expenses | $28,719 | $28,884 | $30,651 | $26,957 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $146,714 | $132,277 | $123,540 | $113,735 |
| Operating Income | -$139,714 | -$132,277 | -$123,540 | -$113,735 |
| % Margin | -1,995.9% | – | – | – |
| Other Income/Exp. Net | $12,541 | $10,445 | $8,102 | $2,041 |
| Pre-Tax Income | -$127,173 | -$121,832 | -$115,438 | -$111,694 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$127,173 | -$121,832 | -$115,438 | -$111,694 |
| % Margin | -1,816.8% | – | – | – |
| EPS | -1.68 | -2.02 | -2.27 | -2.33 |
| % Growth | 16.8% | 11% | 2.6% | – |
| EPS Diluted | -1.68 | -2.02 | -2.27 | -2.33 |
| Weighted Avg Shares Out | 75,806 | 60,357 | 47,372 | 47,602 |
| Weighted Avg Shares Out Dil | 75,806 | 60,357 | 47,372 | 47,602 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1,772 | $1,169 | $1,324 | $915 |
| EBITDA | -$137,942 | -$131,108 | -$122,216 | -$112,820 |
| % Margin | -1,970.6% | – | – | – |